Furthermore, to the best of our knowledge, we are one of the first who evaluated the impact of classic systemic antipsoriatic treatment on gal-3 levels in order to assess its potency to assess the efficacy of certain drugs in psoriasis or perhaps contribute to develop newer therapeutic strategies. Here, LGALS3 is linked to psoriasis.